Equillium Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Equillium Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Equillium Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Equillium Inc. is EQ:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Equillium Inc. has its primary listing on NASDAQ. You can trade Equillium Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Equillium Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Equillium Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Equillium Inc..